Direct-to-consumer genetic testing is under the spotlight after a series of concerning issues at 23andMe.
A data breach, plummeting stock prices, Board resignations and mass staff layoffs have raised questions about the security of customers' genetic information.
23andMe, unlike its closest competitors, offers health-related genetic testing. However, its tests for the BRCA1 and BRCA2 genetic mutations – which have been linked to breast and ovarian cancer – have been found to be inaccurate, fuelling calls for stricter regulation and stronger oversight of the industry.
Read more in the Conversation.
